2026-04-13T02:14:10Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1811242025-12-10T20:14:08Zcom_2072_1057col_2072_478781col_2072_478917

00925njm 22002777a 4500 dc Fernández Nogueira, Patricia author Fuster Orellana, Gemma author Gutierrez-Uzquiza, Álvaro author Gascón, Pere author Carbó Carbó, Neus author Bragado, Paloma author 2021-11-09T14:31:51Z 2021-11-09T14:31:51Z 2021-06-23 2021-11-09T14:31:52Z Breast cancer (BrCa) is the leading cause of death among women worldwide, with about one million new cases diagnosed each year. In spite of the improvements in diagnosis, early detection and treatment, there is still a high incidence of mortality and failure to respond to current therapies. With the use of several well-established biomarkers, such as hormone receptors and human epidermal growth factor receptor-2 (HER2), as well as genetic analysis, BrCa patients can be categorized into multiple subgroups: Luminal A, Luminal B, HER2-enriched, and Basal-like, with specific treatment strategies. Although chemotherapy and targeted therapies have greatly improved the survival of patients with BrCa, there is still a large number of patients who relapse or who fail to respond. The role of the tumor microenvironment in BrCa progression is becoming increasingly understood. Cancer-associated fibroblasts (CAFs) are the principal population of stromal cells in breast tumors. In this review, we discuss the current understanding of CAFs' role in altering the tumor response to therapeutic agents as well as in fostering metastasis in BrCa. In addition, we also review the available CAFs-directed molecular therapies and their potential implications for BrCa management. Càncer de mama Metàstasi Fibroblasts Breast cancer Metastasis Fibroblasts Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.